SGPSpyGlass Pharma, Inc.同业对比
SpyGlass Pharma, Inc. 与Surgical & Medical Instruments & Apparatus的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Surgical & Medical Instruments & Apparatus)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGP本股 | $979M#8 | — | 4.2x#8 | — | — | -36.7%#14 | — | -17.2%#8 | — | — | — | — |
| ATEC | $1.6B#1 | — | — | 2.1x#5 | 25.0%#6 | 11.6%#8 | -10.7%#6 | — | -18.5%#7 | 6#3 | -30.0%#11 | — |
| KMTS | $1.4B#2 | — | 6.5x#11 | 15.2x#14 | 59.0%#3 | -15.6%#12 | -141.6%#15 | -59.2%#14 | -59.5%#11 | 4#7 | 2.9%#8 | — |
| TNDM | $1.2B#3 | — | 9.2x#13 | 1.2x#2 | 7.9%#14 | -113.2%#15 | -18.5%#10 | -157.0%#15 | -26.3%#9 | 3#9 | 41.3%#4 | — |
| IART | $1.2B#4 | — | 1.1x#1 | 0.7x#1 | 1.5%#15 | -7389.9%#16 | -30.2%#12 | -49.5%#13 | -32.1%#10 | 6#3 | 2.0%#9 | — |
| AORT | $1.2B#5 | — | 2.6x#3 | 2.6x#8 | 13.6%#12 | 173.1%#1 | 7.6%#3 | 2.2%#4 | 3.0%#2 | 5#6 | -40.2%#14 | 0.3%#2 |
| PRCT | $1.1B#6 | — | 3.3x#5 | 3.6x#9 | 37.2%#5 | -4.5%#9 | -33.7%#13 | -0.0%#5 | -63.4%#12 | 2#11 | -47.8%#15 | — |
| IRMD | $1.1B#7 | 46.3x#1 | 10.4x#14 | 12.6x#13 | 14.4%#11 | 16.9%#6 | 31.2%#1 | 22.1%#2 | — | — | 17.4%#6 | 1.4%#1 |
| BBNX | $965M#9 | — | 3.8x#7 | 9.6x#12 | 53.9%#4 | -33.7%#13 | -71.5%#14 | -28.6%#12 | — | — | -7.1%#10 | — |
| SIBN | $810M#10 | — | 4.4x#9 | 4.0x#10 | 20.2%#7 | 38.8%#3 | -11.1%#7 | -10.4%#6 | -12.0%#4 | 6#3 | 23.2%#5 | — |
| MDXG | $684M#11 | 117.3x#2 | 3.2x#4 | 1.6x#3 | 20.0%#8 | 14.5%#7 | 15.3%#2 | 22.5%#1 | 48.1%#1 | 8#1 | -32.5%#12 | — |
| SSII | $661M#12 | — | 12.4x#15 | 15.6x#15 | 105.7%#2 | 36.7%#4 | -19.3%#11 | -22.7%#11 | -20.1%#8 | — | -38.2%#13 | — |
| ANGO | $635M#13 | — | 3.7x#6 | 2.0x#4 | 9.5%#13 | -8.1%#11 | -12.5%#8 | -21.5%#9 | -16.5%#6 | 4#7 | 42.0%#3 | — |
| KIDS | $570M#14 | — | 1.7x#2 | 2.4x#7 | 15.4%#10 | -4.8%#10 | -16.6%#9 | -11.5%#7 | -8.6%#3 | 3#9 | 13.4%#7 | — |
| DCTH | $564M#15 | 812.5x#3 | 4.7x#10 | 6.6x#11 | 129.1%#1 | 110.2%#2 | 0.8%#4 | 2.2%#3 | — | 8#1 | 45.2%#2 | — |
| CERS | $535M#16 | — | 7.6x#12 | 2.3x#6 | 16.1%#9 | 25.3%#5 | -3.7%#5 | -22.3%#10 | -15.5%#5 | — | 115.9%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议